The document discusses developing new radiotracers for positron emission tomography (PET) imaging using green fluorescent protein (GFP) technology. This allows for fast, multi-platform synthesis of short-lived radiotracers for indications like pediatric neuroblastoma and Parkinson's disease. Initial targets are developing the methodology, understanding regulatory processes, and conducting animal and clinical studies. The business model involves selling radiotracers and precursors to radiopharmacies, hospitals, and imaging centers.